[Inhibition of gastric acid secretion and motility with trospium chloride].
The present study demonstrated a significant inhibition of gastric acid secretion and gastric motility by parenteral and oral application of trospiumchloride. Oral application of a dose inhibiting gastric acid secretion was not associated with the known side effects of anticholinergic therapy like tachycardia, reduction of salivary secretion and impairment of visual accommodation.
D000284:Administration, Oral; D000328:Adult; D001561:Benzilates; D004341:Drug Evaluation; D005750:Gastric Juice / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009662:Nortropanes / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000494:pharmacology*; D011759:Pyrrolidines / Q000627:therapeutic use
D001561:Benzilates; D009662:Nortropanes; D010276:Parasympatholytics; D011759:Pyrrolidines; C003330:trospium chloride
Hemmung der gastralen Säuresekretion und Motilität durch Trospiumchlorid.